Intervention Review

Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia

  1. Kathrin Bauer1,*,
  2. Michaela Rancea1,
  3. Verena Roloff2,
  4. Thomas Elter3,
  5. Michael Hallek3,
  6. Andreas Engert1,
  7. Nicole Skoetz1

Editorial Group: Cochrane Haematological Malignancies Group

Published Online: 14 NOV 2012

Assessed as up-to-date: 4 JAN 2012

DOI: 10.1002/14651858.CD008079.pub2

How to Cite

Bauer K, Rancea M, Roloff V, Elter T, Hallek M, Engert A, Skoetz N. Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemia. Cochrane Database of Systematic Reviews 2012, Issue 11. Art. No.: CD008079. DOI: 10.1002/14651858.CD008079.pub2.

Author Information

  1. 1

    University Hospital of Cologne, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, Cologne, Germany

  2. 2

    MRC Biostatistics Unit, Cambridge, UK

  3. 3

    University Hospital of Cologne, Department I of Internal Medicine, Center of Integrated Oncology Köln Bonn, Cologne, Germany

*Kathrin Bauer, Cochrane Haematological Malignancies Group, Department I of Internal Medicine, University Hospital of Cologne, Kerpener Str. 62, Cologne, 50924, Germany. kathrin.bauer@uk-koeln.de.

Publication History

  1. Publication Status: New
  2. Published Online: 14 NOV 2012

SEARCH